Bausch Health targets international growth through a six-market expansion of its YUN skincare partnership, aiming to capitalize on momentum from a 13% revenue jump in Q2.
Bausch Health raised full-year guidance and is expanding its YUN probiotic skincare partnership into six new markets, supporting a bullish view despite a flat Diversified segment.
Bausch Health named Bausch + Lomb as part of its ongoing shareholder value evaluation, but no concrete action was announced.
Bausch Health is scaling its microbiome-focused dermatology partnership with YUN into six new international markets, including Mexico and Kazakhstan. This expansion follows a strong second quarter where the company reported a 13% revenue increase to $2.85 billion and raised its full-year guidance, signaling a strategic push to leverage international growth despite flat performance in its domestic Diversified segment.
The partnership allows Bausch Health to gain shelf space in new geographies using YUN's existing live-probiotic technology, avoiding the long development timelines required for in-house product formulas.
Bausch Health has stated it is evaluating all options to unlock shareholder value for both Bausch Health and Bausch + Lomb, though no concrete divestiture or restructuring actions have been announced.